Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2002
12/12/2002WO2002099098A1 Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof
12/12/2002WO2002099096A1 Regulation of human serine/threonine protein kinase-like enzyme
12/12/2002WO2002099093A2 Provision of a putative human hydroxymethyl-glutaryl-coa lyase-like enzyme
12/12/2002WO2002099092A2 Production of recombinant human lysosomal alpha-mannosidase
12/12/2002WO2002099085A2 Human secreted proteins
12/12/2002WO2002099081A2 Methods of using colony stimulating factors in the treatment of tissue damage and ischemia
12/12/2002WO2002099075A2 Prmts as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099074A2 Slc7s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099066A2 20 human secreted proteins
12/12/2002WO2002099062A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
12/12/2002WO2002099061A2 Method of treating alzheimer's disease with se-containing peptide
12/12/2002WO2002099060A2 Dgks as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099040A2 Igs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099038A2 Adsls as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099037A2 Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
12/12/2002WO2002099036A2 Inhibition of neurodegeneration
12/12/2002WO2002099035A2 Chimeric alphavirus replicon particles
12/12/2002WO2002098920A1 Molecules and methods for inhibiting shedding of kim-1
12/12/2002WO2002098917A2 Human proteins and nucleic acids encoding same
12/12/2002WO2002098916A2 Transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent
12/12/2002WO2002098915A2 Compositions and methods for detecting or regulating cholesteryl ester transfer protein
12/12/2002WO2002098914A2 Mutants of igf binding proteins and methods of production of antagonists thereof
12/12/2002WO2002098912A2 Guanylate-cyclase c ligand, administered via the airways, for the treatment of respiratory airway problems
12/12/2002WO2002098910A1 Production of a stress protein
12/12/2002WO2002098909A1 Vaccines
12/12/2002WO2002098908A2 Osteoclastogenesis inhibitory factor, sequence coding for it and uses
12/12/2002WO2002098907A2 Cation conducting gabaa receptors and their use
12/12/2002WO2002098906A1 Methods and compositions for modulating ace-2 activity
12/12/2002WO2002098900A2 Novel human proteins, polynucleotides encoding them and methods of using the same
12/12/2002WO2002098899A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098515A2 Topical treatments using alkanolamines
12/12/2002WO2002098511A1 Compositions comprising oestrone-3-0-sulphamate and trail (tnf-related apoptosis inducing ligand)
12/12/2002WO2002098482A2 System for osmotic delivery of pharmaceutically active agents
12/12/2002WO2002098459A2 USE OF IgM ANTIBODIES AGAINST dsDNA IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS
12/12/2002WO2002098458A1 Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
12/12/2002WO2002098456A2 Antigens and vectors for vaccination
12/12/2002WO2002098455A2 Production of recombinant human arylsulfatase a
12/12/2002WO2002098454A2 Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
12/12/2002WO2002098453A2 Orally administering parathyroid hormone and calcitonin
12/12/2002WO2002098452A1 Mixtures of growth hormone drug-oligomer conjugates compromising polyalkylene glycol, uses thereof, and methods of making same
12/12/2002WO2002098451A1 Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
12/12/2002WO2002098450A1 Altering an immune response by influencing the interaction of lair with its ligand
12/12/2002WO2002098449A1 Remedies for joint injury and functional foods
12/12/2002WO2002098448A1 Methods and compositions for modulating ace-2 activity
12/12/2002WO2002098447A1 Cytotoxic or radioactive conjugates able to bind to oxytocin receptors
12/12/2002WO2002098446A1 Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
12/12/2002WO2002098444A2 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
12/12/2002WO2002098443A2 Stabilised mrna with an increased g/c content and optimised codon for use in gene therapy
12/12/2002WO2002098442A2 Composition containing phytase
12/12/2002WO2002098441A2 Method of treating metabolic disorders using neuronatin polypeptides
12/12/2002WO2002098437A1 Korean acanthopanax senticosus extract, protein extract, crude protein-polysaccharide which were extracted from korean acanthopanax senticosus, and immunoregulating compositions comprising the same and use thereof
12/12/2002WO2002098432A1 Methods of treating cardiac disorders
12/12/2002WO2002098424A1 Novel anti-infectives
12/12/2002WO2002098419A1 Integrin linked kinase modulation of macrophage activation
12/12/2002WO2002098418A1 Combination comprising a p-gp inhibitor and an anti-epileptic drug
12/12/2002WO2002098414A1 Methods using ptpase inhibitors and insulin
12/12/2002WO2002098376A1 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enyzmes
12/12/2002WO2002098373A1 Methods and products for bad breath
12/12/2002WO2002098365A2 Conditioned cell culture media and uses thereof
12/12/2002WO2002098362A2 Use of rank antagonists to treat cancer
12/12/2002WO2002098361A2 T cell induced tissue repair and regeneration
12/12/2002WO2002098360A2 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
12/12/2002WO2002098359A2 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
12/12/2002WO2002098356A2 Ppp2cs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002098351A2 Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within mmp-2
12/12/2002WO2002098348A2 Glp-1 formulations with protracted time action
12/12/2002WO2002098346A2 Method and pharmaceutical composition for the treatment of multiple sclerosis
12/12/2002WO2002098345A1 Use of an antioxidant for treating and/or preventing surface ocular disorders
12/12/2002WO2002098287A2 A high throughput biological heart rate monitor that is molecularly determined
12/12/2002WO2002098286A2 Implantation of biological pacemaker that is molecularly determined
12/12/2002WO2002098278A2 Peripheral blood fibrocytes differentiation pathway and migration to wound sites
12/12/2002WO2002098242A1 Calorically dense liquid oral supplement
12/12/2002WO2002098232A1 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
12/12/2002WO2002089805A3 Use of regularly scheduled high dose intravenous methotrexate therapy
12/12/2002WO2002087600A8 Use of phyllanthus constituents for treating or preventing infections caused by hepatit
12/12/2002WO2002086058A9 Method for producing catalytic antibodies (variants), antigens for immunisation and nucleotide sequence
12/12/2002WO2002085939A8 Novel molecules of the card-related protein family and uses thereof
12/12/2002WO2002083891A3 Nucleic acids for inhibiting hairless protein expression and methods of use thereof
12/12/2002WO2002083164A3 Method and composition for prophylaxis of diabetes
12/12/2002WO2002083081A3 Prostate cancer-related compositions, methods and kits based on dna macroarray protemics platforms
12/12/2002WO2002082044A3 Method of imaging cell death in vivo
12/12/2002WO2002081751A3 A method of increasing endogenous leptin production
12/12/2002WO2002080953A3 Method for reducing cellular damage resulting from hypoxia/ischaemia-related inflammation
12/12/2002WO2002079232A3 Reducing the immunogenicity of fusion proteins
12/12/2002WO2002076508B1 Methods for delivering nucleic acid molecules into cells and assessment thereof
12/12/2002WO2002076494A3 USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
12/12/2002WO2002074798A3 The genome of a bifidobacterium
12/12/2002WO2002074327A3 Compositions and methods for treating gonadotrophin related illnesses
12/12/2002WO2002070552A3 POLYPEPTIDE FROM A HDM2 PROTEIN SPECIFIC MURINE Α/β T-CELL RECEPTORS, NUCLEIC ACIDS CODING FOR THE ABOVE AND USE THEREOF
12/12/2002WO2002068015A9 Modular infusion device and method
12/12/2002WO2002067954A3 Use of particulate biocomplex bk-riv for producing a medicament for protecting and reconstructing the hepatic parenchyma
12/12/2002WO2002067848A3 PEPTIDES FROM THE 16/6id ANTIBODY FOR TREATING SLE
12/12/2002WO2002065989A3 Aminoglycoside treatment for lysosomal storage diseases
12/12/2002WO2002064161A3 Method and compositions for immunization with the pseudomonas v antigen
12/12/2002WO2002064089A3 Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial ib-367 peptides
12/12/2002WO2002062972A3 Hybridoma cell line g250 and its use for producing monoclonal antibodies
12/12/2002WO2002062843A3 Modified erythropoietin (epo) with reduced immunogenicity
12/12/2002WO2002062297A9 Methods and compositions for modulating gluconeogenesis using pgc-1
12/12/2002WO2002061060A3 Two splice variants of the human pftaire serine/threonine kinase
12/12/2002WO2002061058A3 Regulation of human phospholipase
1 ... 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 ... 3163